Bioject Medical Technologies Inc. Meets Final Development Milestone for Merial

PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (OTCBB:BJCT - News), a leading developer of needle-free injection systems, today announced that it has met the final milestone under its Development Agreement with Merial Limited (“Merial”) by delivering devices with auto-disable nozzles to Merial for its next generation spring-powered companion animal vaccination device.

The next generation needle-free spring vaccination device is based on a state-of-the-art needle-free injection technology platform designed for efficient, effective delivery of vaccines and other injectables. The platform is designed to combine high performance standards, dosing flexibility, consistent depth of penetration, and reduced cost. The Merial device is durable and designed for use by veterinarians to deliver vaccines to both feline and canine patients, simply by selection of the appropriate nozzle.

“Merial has learned a great deal from our experience with two companion animal needle free vaccination systems via the Vetjet® device for our Purevax® Feline Leukemia vaccine and the Canine Transdermal Device for our OnceptTM Canine Melanoma Vaccine, DNA. We have been fortunate to have the opportunity to work closely with Bioject to refine this technology into a single device that delivers a variety of vaccines for both species,” said Tim Leard, DVM, PhD, director of Project and Portfolio Management for Merial R&D. Dr. Robert Menardi DVM, director of Companion Animal Vaccines Marketing, said “The benefit of the Bioject device is that it enables precise and efficient delivery of our innovative vaccines, with less stress on dogs and cats.”

“Merial has been an excellent partner and we appreciate the confidence Merial has in our needle-free technology. We are pleased to have completed this final milestone and look forward to using our new platform technology in its first commercial application,” said Ralph Makar, Bioject’s President and CEO.

About Bioject

Bioject Medical Technologies Inc., based in Portland, Oregon, is an innovative developer and manufacturer of needle-free injection therapy systems (NFITS). NFITS provide an empowering technology and works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. Bioject is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.

For more information about Bioject, visit

About Merial

Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs approximately 5,700 people and operates in more than 150 countries worldwide. Its 2009 sales were $2.6 billion. Merial is the Animal Health subsidiary of sanofi-aventis. For more information, please see

This press release contains a forward-looking statement within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the commercialization of the Merial product. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Bioject, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks, uncertainties and other factors include, without limitation, the risk that the product will not be accepted by the market. Readers of this press release are referred to Bioject’s filings with the Securities and Exchange Commission, including the Company’s reports on Form 10-K and Forms 10-Q for further discussions of factors that could affect Bioject’s business and its future results. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. Bioject assumes no obligation to update forward-looking statements if conditions or management’s estimates or opinions should change.


Bioject Medical Technologies Inc. President and CEO Ralph Makar, 503-692-8001 ext. 4137 or EVP and Chief Medical Officer Dr. Richard Stout, 503-692-8001 ext. 4130

Back to news